Statins Cut Heart Risks for People Living With HIV



By Cara Murez 

HealthDay Reporter

THURSDAY, April 13, 2023 (HealthDay Information) — As folks with HIV dwell longer they’re susceptible to untimely coronary heart illness. However a brand new examine finds statin medicine can lower the danger of significant coronary heart issues by greater than one-third.

The U.S. Nationwide Institutes of Well being trial discovered the cholesterol-lowering medicine so efficient, actually, that the examine was stopped early.

Taking the every day statin pitavastatin calcium lowered the danger of main coronary heart occasions by 35% on this affected person group, based on an interim evaluation of information from the Randomized Trial to Stop Vascular Occasions in HIV (REPRIEVE) examine.

“The REPRIEVE examine displays the evolution of HIV science, and progress from focusing totally on approaches to deal with and management the virus to discovering methods to enhance the general well being of individuals residing with HIV,” mentioned Dr. Hugh Auchincloss, appearing director of the Nationwide Institute of Allergy and Infectious Illnesses (NIAID).

“These new information counsel {that a} widespread cholesterol-lowering drugs might considerably enhance cardiovascular outcomes in folks with HIV,” he mentioned in a information launch from the NIH and the NIAID.

As folks with HIV dwell longer because of a long time of medical analysis and advances, untimely coronary heart illness and different power situations have emerged as main causes of sickness and demise.

Statins are recognized to stop coronary heart illness in these in danger within the basic inhabitants. However researchers weren’t sure earlier than the trial if statins would have the identical affect on folks residing with HIV.

REPRIEVE started in 2015 with about 7,800 volunteers aged 40 to 75 years. Greater than 30% had been girls.

The REPRIEVE volunteers had been all taking antiretroviral remedy, and had low-to-moderate conventional heart problems threat that might not sometimes be thought of for statin remedy. The investigators carried out the trial in 12 nations in Asia, Europe, North America, South America and Africa. 

The individuals had been randomly assigned to obtain a every day dose of 4 mg of pitavastatin or a placebo. The researchers monitored them for main coronary heart occasions and adversarial reactions to the treatment. It’s thought of protected to be used with all prescribed antiretroviral remedy regimens.

Unwanted side effects for sufferers had been just like these within the basic inhabitants taking statin remedy, the findings confirmed.

At its most up-to-date assembly, the examine’s Information Security and Monitoring Board decided that the advantages outweighed any dangers.

Examine individuals will proceed to be monitored for a number of months. Outcomes from a last overview are anticipated to be printed within the coming weeks.

“These newest findings characterize the end result of an unprecedented eight-year effort to generate proof that may assist clinicians higher help the distinctive cardiovascular well being wants of individuals residing with HIV,” mentioned Dr. Gary Gibbons, director of the U.S. Nationwide Coronary heart, Lung, and Blood Institute. “REPRIEVE is necessary as a result of there are restricted present interventions to assist forestall adversarial cardiovascular outcomes on this inhabitants.”

Extra data

The U.S. Facilities for Illness Management and Prevention has extra on residing with HIV.


SOURCE: U.S. Nationwide Institutes of Well being/Nationwide Institute of Allergy and Infectious Illnesses, information launch, April 11, 2023